JelloX Biotech Inc. is a startup company focusing on open innovation in translating 3D digital pathology imaging with AI-empowered analysis into precision diagnosis solution. Proprietary technologies enable 3D image-inspired AI models to facilitate spatial feature recognition and 3D pathology parameters including recent publication of lung cancer PD-L1 biomarker profiling for 3D TPS evaluation with better concordance to IO drug treatment outcome, and prostate cancer whole lumen morphology for 3D Gleason scoring with rapid process. We have developed perineural invasion AI model for oral cancer, and H&E image-based fluorescence nuclear detection AI model for breast cancer. JelloX 3D + AI solution is compatible with current pathology workflow allowing subsequent H&E, IHC, and genetic tests to establish an innovative Panoramic Pathology Platform in support of multidimensional tumor atlas analyses. Meanwhile, JelloX MetaLite software with CPU-based edge AI solution has become Intel Market Ready Solution for partnership in business development. JelloX digital pathology platform with federated learning (FL) modules is integrated with Roche Diagnostic system as a powerful AI+FL solution for smart hospital and modern reference lab in support of precision medicine and drug development. JelloX Biotech is now seeking for partnership to boost global market penetration and company valuation.
我們正在追蹤 JelloX Biotech Inc. 的市場擴張
JelloX Biotech Inc. 的國際擴張與競爭對手的比較
JelloX Biotech Inc.你長條顯示所比較各公司之間的相對規模。
欄位5| 公司 | 市場 | 新市場 | 動能 | 活動 | 擴張評分 |
|---|---|---|---|---|---|
 JelloX Biotech Inc.你 | 0 | 0 | — | 0 | 0 |
目前並無招聘
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
無進行中的廣告活動
註冊以追蹤此公司，並在發生變化時第一時間獲得提醒。
JelloX Biotech 揭示人工智能驅動的 3D 數字病理學願景，與美國主要醫療機構合作，利用先進技術改善癌症患者護理成果。
JelloX生物科技公佈AI驅動3D數字病理學願景，致力於以患者為中心的護理，全球合作改善癌症診斷和治療結果。
解鎖已驗證電郵與直撥電話
免費 · 無需信用卡
關於 JelloX Biotech Inc. 業務、市場及增長訊號的快速解答。
